Full-Time

Sustaining Engineer

Jupiter Endovascular

Jupiter Endovascular

51-200 employees

Develops and sells endovascular cardiovascular devices

Compensation Overview

$90k - $105k/yr

+ Equity + 401(k) match

Menlo Park, CA, USA

In Person

Bachelor's

Category
Mechanical Engineering (1)
Required Skills
FDA Regulations
Quality Assurance (QA)
Data Analysis

Get referred to Jupiter Endovascular

See people who can refer or advise you

Requirements
  • A bachelor's degree in engineering or a related field is required.
  • At least 3 years of experience in a related role is required.
  • Experience with root cause analysis is required.
  • Strong communication and presentation skills are required.
  • Ability to work independently in a fast-paced environment while managing changing priorities is required.
  • A demonstrated desire to work in a small medical device startup is required.
Responsibilities
  • Drive continuous improvement of products, processes, and suppliers.
  • Lead and execute sustaining projects by following change-control procedures.
  • Manage internal and external communication for sustaining projects.
  • Perform verification and validation testing required to implement changes.
  • Collaborate with Operations and Product Development to identify supply chain risks.
  • Perform root cause analysis investigations of component failures and non-conformances.
  • Collaborate with suppliers and internal teams to implement corrective actions.
  • Support resolution of customer complaint investigations related to component issues.
  • Perform statistical analysis of data and recommend supplier corrective actions based on process monitoring and statistical process controls.
  • Collaborate with Quality and Product Development to define component inspection requirements.
  • Recommend improvements to next-generation products and processes based on root-cause investigations.
  • Support supplier development, qualification, and capacity scale-up to meet forecasted demand.
  • Collaborate with suppliers to create and execute validation plans.
  • Recommend suppliers for next-generation component development.
  • Identify, develop, and qualify new suppliers as required to mitigate supply chain risks.
  • Create and maintain quality management system documentation related to sustaining projects.
  • Recommend improvements to standard operating procedures and work processes.
  • Work within a regulated, quality-system-driven, FDA-monitored medical device environment.
Desired Qualifications
  • Medical device experience is preferred.
  • Experience with process validation, including installation qualification, operational qualification, and performance qualification, is preferred.
  • Experience with supplier quality is a plus.
  • A strong desire to lead continuous improvement initiatives is desirable.

Jupiter Endovascular develops and sells advanced endovascular devices to improve cardiovascular health, serving hospitals and cardiovascular clinics worldwide. Its products are catheter-based tools used in endovascular procedures, developed, cleared by regulators, and clinically validated before being sold to healthcare providers. The company differentiates itself through a strong focus on clinical affairs and product management, plus a global market presence and strategic partnerships to broaden reach while prioritizing safety and proven efficacy. Its goal is to improve patient cardiovascular outcomes by delivering reliable, clinically validated endovascular solutions to healthcare providers around the world.

Company Size

51-200

Company Stage

Series B

Total Funding

$40M

Headquarters

Menlo Park, California

Founded

N/A

Get referred to Jupiter Endovascular

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Series B closed above $40 million on October 7, 2025, funding SPIRARE II and launch prep.
  • FDA cleared the Vertex Catheter in 2025, de-risking platform components for broader use.
  • Positive SPIRARE II results and new CMO strengthen partnering leverage before 2026 regulatory filings.

What critics are saying

  • Vertex remains investigational; U.S. and Europe commercial sales are blocked today.
  • SPIRARE II studied 123 patients; one disappointment with regulators can delay launch into 2027.
  • No public reimbursement, manufacturing scale, or post-market infrastructure exists; execution failure kills the company.

What makes Jupiter Endovascular unique

  • TFX decouples flexible navigation from stable support in pulmonary arteries.
  • Vertex Thrombectomy System delivered 39% RV/LV reduction and 100% technical success on May 20, 2026.
  • Jupiter hired interventional cardiologist Catalin Toma, MD, as CMO on August 13, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

Remote Work Options

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

22%

1 year growth

22%

2 year growth

22%
Cardiac Vascular News
Aug 13th, 2026
Jupiter Endovascular appoints catalin Toma, MD, as Chief Medical Officer.

Jupiter Endovascular appoints catalin Toma, MD, as Chief Medical Officer. More in financial: MENLO PARK, Calif.-(BUSINESS WIRE)- #TFX-Jupiter Endovascular appoints renowned interventional cardiologist Dr. Catalin Toma as Chief Medical Officer See full post here as originally published on this site

FinSMEs
Oct 7th, 2025
Jupiter Endovascular Closes Series B Funding

Jupiter Endovascular, a Menlo Park, CA-based medical technology startup, closed its Series B funding at over $40M

StockTitan
Oct 7th, 2025
Jupiter Endovascular Raises Over $40M Series B

Jupiter Endovascular closed an oversubscribed Series B financing round, surpassing its $40 million target. Led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor, the funds will support the SPIRARE II clinical trial, commercialization, and new applications for its TFX technology. The Vertex Catheter with TFX recently received FDA 510(k) clearance, and SPIRARE I trial results will be presented at TCT 2025.

MD+DI
Oct 7th, 2025
Jupiter Endovascular Surpasses Funding Goal, Hits FDA Milestone

Jupiter Endovascular has raised over $40M in Series B funding led by Sonder Capital to advance its TFX platform and SPIRARE II trial.

MPO Magazine
Feb 26th, 2025
Jupiter Endovascular Hires Fred Ong as Finance Chief

Jupiter Endovascular revealed that experienced medtech finance and operations exec Fred Ong has joined the company as chief financial officer (CFO).